FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
- 1	haiisa mas saanaaaa.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Hineline Lawrence J.						2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ITCI]								heck all a Di	tionship of Reporting all applicable) Director Officer (give title		g Person(s) to Issuer 10% Owne Other (spec		vner	
	`	JLAR THERAP	(Middle) PIES, INC	Ξ.		Date (Earliest Transaction (Month/Day/Year) 20							ow)			below)	specify	
(Street) NEW Y(10016 (Zip)		_ 4. l ⁻	4. If Amendment, Date of Original Filed (Month/Day/Year)								ne) <mark>X</mark> Fo Fo	<i>'</i>					
		Tab	ole I - No	on-Deri	vative	e Se	curit	ies Ac	quired	, Dis	sposed o	of, or Be	neficia	Ily Owi	ned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					tion 2A. Deemed Execution Date,		3. 4. Transaction Code (Instr.			4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a		or 5. Amou Securiti Benefici Owned		s Illy ollowing	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
										v	Amount	(A) or (D)	Price	Trai	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 11				11/11	/2020				M		10,000	A	A \$2.8		18,034			D		
Common Stock 11/11				/2020	2020			M		10,000) A \$		6	28,034			D			
Common Stock 11/11/2				/2020	2020			S		28,034	D	\$25.4	1(1)	0			D			
		-	Table II						,		osed of, convertil			y Owne	d					
1. Title of Derivative Security 1. Title of Derivative Security 2. Conversion or Exercise (Month/Day/Year) 3. Transaction Date Execution I if any (Month/Day Month/Day Month/				n Date,	Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)		te	7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price Deriva Securi (Instr. !	ive y	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e C s F lly C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	٧	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares							
Stock Option (right to buy)	\$2.84	11/11/2020			М			10,000	(2)		04/30/2022	Common Stock	10,000	\$0.0)	0		D		
Stock Option (right to	\$3.26	11/11/2020			М			10,000	(2)		05/30/2023	Common Stock	10,000	\$0.0		0		D		

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$25.73 to \$25.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 2. All shares underyling this option have vested.

Remarks:

/s/ Lawrence J. Hineline

11/13/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.